^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AMY109
i
Other names: AMY109, AMY 109 subcutaneous, AMY109 SC, AMY109 intravenous, AMY109 IV, Recycling antibody, AMY 109, AMY-109
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
IL-8 inhibitor
Related drugs:
over1year
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers. (PubMed, J Immunother Cancer)
With no DLTs, AMY109 plus atezolizumab was well tolerated in patients with advanced solid tumors, with no new safety signals. AMY109 showed a dose-proportional increase in exposure. The PRs in two patients were durable.
P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CXCL8 (Chemokine (C-X-C motif) ligand 8)
|
Tecentriq (atezolizumab) • AMY109
over2years
Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours (ESMO 2023)
With no DLTs, AMY109 plus atezo was well tolerated in pts with advanced solid tumours, with no new safety signals. The partial responses were durable.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CXCL8 (Chemokine (C-X-C motif) ligand 8)
|
Tecentriq (atezolizumab) • AMY109
Share via
